Alkaptonuria (AKU), sometimes called “black urine disease,” is a rare genetic condition where the body cannot properly break down certain amino acids, causing urine to darken when exposed to air and, over decades, leading to progressive arthritis and other complications from pigment buildup in connective tissue. This guide covers the genetics, symptoms, and treatment landscape for this rare metabolic disorder.
This is general information, not medical advice.
What causes alkaptonuria
AKU is caused by a deficiency in an enzyme called homogentisate 1,2-dioxygenase (HGD), resulting from mutations in the HGD gene. This enzyme is normally needed to break down homogentisic acid, an intermediate substance produced during the body’s breakdown of the amino acids tyrosine and phenylalanine. Without functional HGD, homogentisic acid accumulates in the body and is excreted in large amounts through urine (typically 1 to 8 grams per day). It’s inherited in an autosomal recessive pattern, meaning a person needs two altered copies of the gene (one from each parent) to be affected; parents who each carry a single altered copy typically show no symptoms themselves. AKU is rare, affecting an estimated 1 in 100,000 to 1 in 1,000,000 people worldwide, with notably higher rates reported in Slovakia and the Dominican Republic.
The three hallmark features
- Dark urine, urine that turns dark brown or black when exposed to air (oxidation), often the first noticeable sign, sometimes visible as dark staining in an infant’s diaper, though this frequently goes unnoticed since the color change can take hours to appear
- Ochronosis, a bluish-black pigmentation that builds up in connective tissue over time, generally becoming apparent after around age 30, visible in places like the whites of the eyes, the ears, and the skin
- Arthritis, particularly affecting the spine and larger joints, which often begins in the third or fourth decade of life and progressively worsens
Why the condition often goes unnoticed for decades
Because the dark urine sign is present from birth but frequently overlooked (the color change takes hours and isn’t always obvious), and because the more debilitating features, ochronosis and arthritis, don’t typically appear until adulthood, many people with AKU aren’t diagnosed until they’re evaluated for joint problems in their 40s or later, despite having had the underlying condition since birth.
Long-term complications
Beyond joint and spine arthritis, which frequently requires joint replacement surgery over time given the progressive connective tissue degeneration involved, AKU can also affect the cardiovascular system, notably including aortic valve disease. One study following AKU patients found aortic stenosis (narrowing of the aortic heart valve) in over 20% of those studied, and a meaningful proportion eventually required aortic valve replacement. Despite these significant complications, life expectancy for people with AKU is generally considered normal; the disease’s main impact is on quality of life and progressive morbidity rather than shortened lifespan.
Diagnosis
Diagnosis is based on detecting a significant amount of homogentisic acid in urine testing, and molecular genetic testing (identifying the specific HGD gene mutations) can confirm the diagnosis and support genetic counseling for family members who may be carriers.
Treatment
There is a real, targeted treatment worth knowing about: nitisinone, a medication that has been shown to slow the progression of AKU symptoms by reducing homogentisic acid production. It’s important to know its regulatory status differs by region: nitisinone is approved for treatment of alkaptonuria in Europe, but not currently approved for this specific use in the United States, meaning access and treatment options can differ significantly depending on where a patient is located. Beyond nitisinone where available, management generally focuses on symptom control: pain management for arthritis, physical therapy, and monitoring and treatment of cardiovascular complications, including valve replacement surgery when needed.
Frequently asked questions
Why is alkaptonuria called “black urine disease”?
Because the urine of affected individuals turns dark brown or black when exposed to air, due to oxidation of the excess homogentisic acid the body cannot properly break down.
Is there a cure for alkaptonuria?
There is no cure, but nitisinone, available as an approved treatment in Europe (not currently FDA-approved in the US for this specific use), has been shown to slow disease progression by reducing homogentisic acid production.
Does alkaptonuria shorten life expectancy?
Generally, no; life expectancy is considered normal, though the condition carries a significant burden of progressive joint, spine, and cardiovascular complications that meaningfully affect quality of life starting in adulthood.
How is alkaptonuria inherited?
It’s an autosomal recessive genetic condition, meaning a person needs two altered copies of the HGD gene (one from each parent) to be affected; carriers with only one altered copy typically show no symptoms.
At what age do alkaptonuria symptoms usually appear?
Dark urine is present from birth, though often unnoticed. The more debilitating features, ochronosis and arthritis, typically don’t become apparent until around age 30 or later.